Foamix Pharmaceuticals (NASDAQ:FOMX) announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04), Morningstar.com reports. Foamix Pharmaceuticals had a negative net margin of 2,115.11% and a negative return on equity of 79.46%. The business had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.95 million.
Shares of FOMX stock traded up $0.01 during midday trading on Friday, reaching $2.45. 128,238 shares of the stock were exchanged, compared to its average volume of 331,464. The company has a market capitalization of $127.36 million, a price-to-earnings ratio of -1.44 and a beta of 1.60. Foamix Pharmaceuticals has a 1 year low of $2.30 and a 1 year high of $7.60.
In related news, insider Matthew T. Wiley purchased 13,440 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The shares were bought at an average price of $3.76 per share, for a total transaction of $50,534.40. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Anna Kazanchyan sold 10,600 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $2.61, for a total value of $27,666.00. Following the completion of the sale, the director now owns 55,955 shares in the company, valued at approximately $146,042.55. The disclosure for this sale can be found here. Insiders sold a total of 19,911 shares of company stock worth $62,582 in the last 90 days. 2.95% of the stock is currently owned by company insiders.
A number of research analysts recently issued reports on FOMX shares. Cowen set a $30.00 price target on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Friday, March 1st. Cantor Fitzgerald restated a “buy” rating and set a $15.00 price target on shares of Foamix Pharmaceuticals in a report on Tuesday, April 2nd. ValuEngine downgraded Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Finally, HC Wainwright set a $12.00 target price on Foamix Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. Foamix Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $14.75.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Rockland Register and is the property of of Rockland Register. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://rocklandregister.com/2019/05/31/foamix-pharmaceuticals-fomx-posts-earnings-results-misses-expectations-by-0-04-eps.html.
Foamix Pharmaceuticals Company Profile
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea.
Featured Story: How Do Tariffs Affect Trade Balances?
Receive News & Ratings for Foamix Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.